Exploratory analysis of prognostic factors for lenvatinib in radioiodine‐refractory differentiated thyroid cancer
-
- Chiaki Suzuki
- Department of Medical Oncology/Hematology Kobe University Graduate School of Medicine Kobe Japan
-
- Naomi Kiyota
- Department of Medical Oncology/Hematology Kobe University Graduate School of Medicine Kobe Japan
-
- Yoshinori Imamura
- Department of Medical Oncology/Hematology Kobe University Graduate School of Medicine Kobe Japan
-
- Hideaki Goto
- Department of Medical Oncology/Hematology Kobe University Graduate School of Medicine Kobe Japan
-
- Hirotaka Suto
- Department of Medical Oncology/Hematology Kobe University Graduate School of Medicine Kobe Japan
-
- Naoko Chayahara
- Department of Medical Oncology/Hematology Kobe University Graduate School of Medicine Kobe Japan
-
- Masanori Toyoda
- Department of Medical Oncology/Hematology Kobe University Graduate School of Medicine Kobe Japan
-
- Yasuhiro Ito
- Department of Surgery Kuma Hospital Kobe Japan
-
- Akihiro Miya
- Department of Surgery Kuma Hospital Kobe Japan
-
- Akira Miyauchi
- Department of Surgery Kuma Hospital Kobe Japan
-
- Naoki Otsuki
- Department of Otolaryngology‐Head and Neck Surgery Kobe University Graduate School of Medicine Kobe Japan
-
- Ken‐ichi Nibu
- Department of Otolaryngology‐Head and Neck Surgery Kobe University Graduate School of Medicine Kobe Japan
-
- Hironobu Minami
- Department of Medical Oncology/Hematology Kobe University Graduate School of Medicine Kobe Japan
Description
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Multitarget kinase inhibitors (m‐TKI), including lenvatinib, are now available as treatment options for radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). However, the optimal timing of treatment initiation with m‐TKI in these patients remains to be defined.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We retrospectively reviewed the clinical records of 30 consecutive patients with RR‐DTC. The relationship between clinical characteristics was evaluated, including tumor growth parameters at pretreatment/post‐treatment and efficacy of lenvatinib.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 26 patients with RR‐DTC treated with lenvatinib were evaluable for response and eligible for analysis. From the results of multivariate analysis, baseline tumor size and tumor‐related symptoms were independent negative prognostic factors for overall survival (OS) and progression‐free survival (PFS). Pretreatment tumor growth parameters were not prognostic for either PFS or OS.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Patients with RR‐DTC with a high tumor burden and tumor‐related symptoms had significantly worse prognosis. Greater tumor reduction after starting lenvatinib may lead to better prognosis, irrespective of pretreatment high tumor growth rate.</jats:p></jats:sec>
Journal
-
- Head & Neck
-
Head & Neck 41 (9), 3023-3032, 2019-04-23
Wiley